Loading data for VTGN — first visit, this takes a few seconds.

알림

Vistagen Therapeutics Inc... (VTGN)

NasdaqCM: VTGN · 실시간 가격 · USD

0.24

+0.00 (0.00%)

종가 기준: Aug 19, 2026, 8:00 PM

0.24

+0.00%

애프터마켓: 4:04 PM

주가와 핵심 숫자, 최신 뉴스를 한 곳에 모았습니다.

0.00% (1D)

데이터 없음

매수호가	0.19
시가총액	10.83M
매출 (ttm)	1.27M
순이익 (ttm)	-69.69M
	0.38
	-1.66
	n/a
	-0.16
P/B (ttm)	0.27
P/S (ttm)	8.54
실적 발표일	Aug 14, 2026

매도호가	0.33
거래량	403,661
평균 거래량 (20일)	4,094,456
시가	0.25
전일 종가	0.24
일중 범위	0.24 - 0.25
52주 범위	0.20 - 5.14
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

VTGN 소개

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherin...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jun 21, 2011

직원 수 41

상장 거래소 NasdaqCM

티커 VTGN

웹사이트 https://www.vistagen.com

전체 기업 정보

재무 실적

2026년 Vistagen Therapeutics의 매출은 1.27M로, 전년 486K 대비 161.11% 증가했습니다. 순이익은 -69.69M로, 35.53% 증가했습니다.

재무제표

어닝 서프라이즈

Vistagen Therapeutics가 Jun 15, 2026에 분기 실적을 발표했습니다:

매출 $465K 예상치 하회 $0, 및 -3200.00% 전년 대비 감소.

EPS -0.37 예상치 하회 -0.10, 및 15.91% 전년 대비 성장.

다음 실적 발표

Vistagen Therapeutics Inc.의 실적 발표 예정일은 Aug 14, 2026, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

2주 전 · InvestorsHub

SRX Global Acquires Stake in Vistagen Therapeutics

SRX Global (AMEX:SRXH) disclosed an investment in Vistagen Therapeutics (NASDAQ:VTGN) and said it intends to engage with the company’s leadership and board on potential shareholder value initiatives. ...

1개월 전 · Insider Monkey

Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results?

We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is one of the best psychedelic stocks on our list. TheFly reported ...

2개월 전 · Zacks

HealthEquity (HQY) Q1 Earnings and Revenues Top Estimates

HealthEquity (HQY) delivered earnings and revenue surprises of +11.57% and +0.06%, respectively, for the quarter ended April 2026. Do the numbers hold clues to what lies ahead for the stock?

3개월 전 · Zacks

Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Montes Archimedes Acquisition (ROIV) delivered earnings and revenue surprises of -41.18% and -8.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for th...

3개월 전 · Insider Monkey

Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results?

We recently compiled a list of the 10 Best Penny Stocks Under $1 According to Hedge Funds. Vistagen Therapeutics, Inc. (NASDAQ:VTGN) is also among the best penny stocks. TheFly reported on May 12 that...

2 페이지 중 1

Vistagen Therapeutics Inc... (VTGN)